Perspective Therapeutics has begun enrolling participants into the next phase of its clinical trial of a new targeted alpha radiation therapy for neuroendocrine tumors (NETs). The trial is evaluating a radiopharmaceutical called [212Pb]VMT-α-NET, which delivers radiation directly to cancer cells that have a specific receptor called somatostatin (SSTR2) on their surface.
The study is now moving into its third dosing group (Cohort 3), where patients will receive a slightly higher dose than in previous groups. This phase of the trial follows earlier participants who tolerated the treatment well and showed early signs that it may help shrink tumors.
The trial is open to people with advanced NETs, including GEP-NETs, lung NETs, and pheochromocytoma/paraganglioma, who haven’t yet received peptide receptor radionuclide therapy (PRRT). Participants in Cohort 3 will receive up to four doses of [212Pb]VMT-α-NET, spaced eight weeks apart.
The treatment approach uses a special type of radiation called 212Pb that’s designed to more precisely target cancer cells, potentially limiting damage to healthy tissue. Perspective Therapeutics aims to personalize treatment by combining therapy with imaging tools that can show exactly where the cancer is in the body.
Visit clinicaltrials.gov to learn more about the trial.